- Report
- January 2026
- 180 Pages
Global
From €3458EUR$3,939USD£3,008GBP
- Report
- January 2026
- 181 Pages
Global
From €3458EUR$3,939USD£3,008GBP
- Report
- August 2025
- 189 Pages
Global
From €3458EUR$3,939USD£3,008GBP
- Report
- January 2026
- 198 Pages
Global
From €3458EUR$3,939USD£3,008GBP
- Report
- August 2025
- 180 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- February 2025
- 182 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- February 2026
- 604 Pages
Global
From €5135EUR$5,850USD£4,467GBP
- Report
- February 2025
- 150 Pages
Global
From €3379EUR$3,850USD£2,940GBP
€4257EUR$4,850USD£3,704GBP
- Report
- September 2023
- 374 Pages
Global
From €4345EUR$4,950USD£3,780GBP
- Report
- June 2022
- 300 Pages
Global
From €3160EUR$3,600USD£2,749GBP
Fresh Frozen Plasma (FFP) is a component of blood banking that is used to treat a variety of medical conditions. It is a liquid form of blood plasma that has been frozen and stored for later use. FFP is used to treat conditions such as bleeding disorders, immune deficiencies, and shock. It is also used to replace lost blood volume and to provide clotting factors for patients with clotting disorders. FFP is collected from healthy donors and is then tested for infectious diseases before being frozen and stored.
FFP is a vital component of the blood banking industry, as it is used to treat a variety of medical conditions. It is also used in research and development of new treatments and therapies.
Some companies in the FFP market include Grifols, CSL Behring, Octapharma, and Kedrion Biopharma. Show Less Read more